Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment

CONCLUSION: Frail patients treated with PVd demonstrated a higher ORR and a longer PFS and DoT vs. Vd, despite a higher frequency of grade ≥ 3 TEAEs leading to pomalidomide, bortezomib, and/or dexamethasone discontinuation. Therefore, PVd treatment may improve patient outcomes, regardless of frailty.PMID:38072743 | DOI:10.1016/j.clml.2023.10.009

Source: Clinical Lymphoma and Myeloma - December 10, 2023 Category: Cancer & Oncology Authors: Albert Oriol Meletios Dimopoulos Fredrik Schjesvold Meral Beksac Thierry Facon Sujith Dhanasiri Shien Guo Yutian Mu Kevin Hong Christian Gentili Monica Galli Munci Yagci Alessandra Larocca Paul Richardson Katja Weisel Source Type: research